Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).
Read the original article

Tags:

Previous Article

KAIST develops sodium battery capable of rapid charging in just a few seconds​

Next Article

PRO-1107 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

Merus’ Bizengri granted FDA accelerated approval to tre...

Dec 7, 2024

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Organon makes $1.2bn play for Roivant’s immuno-dermatol...

Sep 20, 2024

ZyVersa Therapeutics inches closer to European patent approval for VAR 200

ZyVersa Therapeutics inches closer to European patent a...

Jun 7, 2023